These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18089462)

  • 21. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential.
    Dame C; Juul SE; Christensen RD
    Biol Neonate; 2001; 79(3-4):228-35. PubMed ID: 11275657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythropoietin improves spatial delayed alternation in a T-maze in rats subjected to ablation of the prefrontal cortex.
    Mogensen J; Boyd MH; Nielsen MD; Kristensen RS; Malá H
    Brain Res Bull; 2008 Sep; 77(1):1-7. PubMed ID: 18639740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia.
    van der Kooij MA; Groenendaal F; Kavelaars A; Heijnen CJ; van Bel F
    Brain Res Rev; 2008 Nov; 59(1):22-33. PubMed ID: 18514916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erythropoietin and its non-erythropoietic derivative: do they ameliorate renal tubulointerstitial injury in ureteral obstruction?
    Srisawat N; Manotham K; Eiam-Ong S; Katavetin P; Praditpornsilpa K; Eiam-Ong S
    Int J Urol; 2008 Oct; 15(11):1011-7. PubMed ID: 18759748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection of erythropoietin on experimental spinal cord injury by reducing the expression of thrombospondin-1 and transforming growth factor-beta.
    Fang XQ; Fang M; Fan SW; Gu CL
    Chin Med J (Engl); 2009 Jul; 122(14):1631-5. PubMed ID: 19719963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis.
    Kadota T; Shingo T; Yasuhara T; Tajiri N; Kondo A; Morimoto T; Yuan WJ; Wang F; Baba T; Tokunaga K; Miyoshi Y; Date I
    Brain Res; 2009 Feb; 1254():120-7. PubMed ID: 19101524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants].
    He JS; Huang ZL; Yang H; Weng KZ; Zhu SB
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Oct; 10(5):586-8. PubMed ID: 18947475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants.
    Fauchère JC; Dame C; Vonthein R; Koller B; Arri S; Wolf M; Bucher HU
    Pediatrics; 2008 Aug; 122(2):375-82. PubMed ID: 18676556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythropoietin in cancer: the new face of an old friend.
    Megalakaki C
    J BUON; 2008; 13(1):7-16. PubMed ID: 18404780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anemia in chronic heart failure: etiology and treatment options.
    Westenbrink BD; de Boer RA; Voors AA; van Gilst WH; van Veldhuisen DJ
    Curr Opin Cardiol; 2008 Mar; 23(2):141-7. PubMed ID: 18303527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel neurotrophic therapeutic strategy for experimental stroke.
    Belayev L; Khoutorova L; Zhao KL; Davidoff AW; Moore AF; Cramer SC
    Brain Res; 2009 Jul; 1280():117-23. PubMed ID: 19463796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease.
    Hasselblatt M; Ehrenreich H; Sirén AL
    J Neurosurg Anesthesiol; 2006 Apr; 18(2):132-8. PubMed ID: 16628067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythropoietin reduces epileptogenic processes following status epilepticus.
    Chu K; Jung KH; Lee ST; Kim JH; Kang KM; Kim HK; Lim JS; Park HK; Kim M; Lee SK; Roh JK
    Epilepsia; 2008 Oct; 49(10):1723-32. PubMed ID: 18479396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO).
    Kirkeby A; Torup L; Bochsen L; Kjalke M; Abel K; Theilgaard-Monch K; Johansson PI; Bjørn SE; Gerwien J; Leist M
    Thromb Haemost; 2008 Apr; 99(4):720-8. PubMed ID: 18392330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure.
    van der Putten K; Braam B; Jie KE; Gaillard CA
    Nat Clin Pract Nephrol; 2008 Jan; 4(1):47-57. PubMed ID: 18094727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of erythropoietin after solid organ transplantation.
    Schwenger V; Morath C; Zeier M
    Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii47-viii49. PubMed ID: 17890262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medicine. A boost for translational neuroscience.
    Ehrenreich H
    Science; 2004 Jul; 305(5681):184-5. PubMed ID: 15247460
    [No Abstract]   [Full Text] [Related]  

  • 39. Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle.
    Mannello F; Tonti GA
    Oncologist; 2008 Jul; 13(7):761-8. PubMed ID: 18596367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uncoupling of neurodegeneration and gliosis in a murine model of juvenile cortical lesion.
    Sargin D; Hassouna I; Sperling S; Sirén AL; Ehrenreich H
    Glia; 2009 May; 57(7):693-702. PubMed ID: 18985736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.